MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis
ConditionCystic Fibrosis (CF)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1+
SponsorSheffield Teaching Hospitals NHS Foundation Trust
About this trial
This research study is looking at new ways of measuring the function of the lungs in patients with cystic fibrosis. This study is using the most advanced methods for measuring lung function including 2 tests called hyperpolarised gas magnetic resonance imaging (HP MRI) and multiple breath washout (MBW), to better understand changes in the lungs over time.
HP MRI involves taking pictures of the air in your lungs after breathing in a harmless gas (xenon). MBW is a breathing test used to calculate something called the lung clearance index (LCI).
By measuring these tests on the same day, alongside standard lung function tests, we aim to understand lung function in greater detail than ever before.
Eligibility criteria
Qualifiers
A confirmed clinical diagnosis of CF, consisting of 2 confirmed disease-causing CFTR mutations along with either positive sweat chloride (>60mmol/L, measured before starting CFTR modulator therapy) or a clinical picture consistent with CF as judged by a senior CF physician. Patients will be under one of named regional CF centres above.
Be able to attend the local facility for scans (Royal Hallamshire Hospital, Sheffield).
Aged 5 years and above
FEV1 >30% predicted (best in the previous 6 months) For eligibility for cohort 1
Disqualifiers
Previous lung transplant.
Infection with organisms of the Burkholderia cepacia complex, MRSA or Mycobacterium abscessus.
Pregnancy.
Resting SpO2 < 90% in room air.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 5 trial groupsSponsors and collaborators
Sheffield Teaching Hospitals NHS Foundation Trust
Lead sponsor
University of Sheffield
Collaborator
Source ClinicalTrials.gov